Connect with your colleagues through the Dermatology Times nurse practitioner and physician assistant online discussion forum―inspired by and created for our readers to discuss patient and professional issues affecting NPs and PAs
Blossom Innovations LLC, a medical technology company specializing in dermatology, announces its next success, a cold-based medical device technology to address pigmentation issues related to aging, sun damage, and genetics.
We've gathered our latest and greatest articles on excessive sweating so you can sit back and relax over the holiday. From a new topical to Botox to treatments yet to come, our slideshow contains all you need to know about novel hyperhidrosis treatments.
Long lauded for its ability to reduce the appearance of wrinkles, botulinum toxin is now being considered for reducing scarring.
Cosmetic product ingredient mixtures linked to hormonal changes in women according to research.
Two leading industry meetings will offer diverse education and networking opportunities next month. Featured technologies range from new and established energy-based devices for anti-aging treatments, tattoo removal and body contouring, to a host of microneedling devices.
Study of 144 female students shows that stress may increase acne severity.
In June, Dermira Inc. announced the FDA approval of Qbrexza (glycopyrronium) for primary axillary hyperhidrosis ― excessive underarm sweating.
Here's a look at new botulinum toxin treatments on the horizon.
Options include a new FDA-approved topical, injections and energy. Dee Anna Glaser, M.D., shares patient profiles and use considerations for each.